Catabasis Pharmaceuticals, a US-based healthcare company treating inflammation, has raised a further $9m, according to a regulatory filing seen by news provider Fierce Biotech.
In December 2011, Catabasis extended its series A round by $8m to take its total raised to $47.6m from a consortium including drugs group AstraZeneca’s MedImmune Ventures corporate venturing unit.
All other current investors participated in the third financing extension, including venture capital firms SV Life Sciences, Clarus Ventures and Advanced Technology Ventures.